Share

Thermo Fisher Scientific Inc. (TMO.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Neutral

5-Year Return Est.

+39.4%

Includes 0.19% annual net dividend contribution

1. Investment Thesis — Base Case

The central tension is straightforward: an excellent business bought at a price that already assumes the recovery arrives on schedule. Thermo Fisher's operating inflection is genuine, organic growth moved from 1% to 5% within two quarters and guidance rose, but the market repriced that inflection in four months, lifting the stock roughly 45% from May's low and through the mean analyst target. Over five years, low-double-digit adjusted EPS compounding meets gradual multiple compression as a 5% ten-year yield reasserts itself. Shareholders earn the earnings growth minus the de-rating, which is a respectable but unspectacular mid-single-digit annual return.

Adjusted EPS of roughly $25 in 2026 compounding near 10% implies about $40 by 2031.
Applying a 21-22x forward multiple, down from today's 25.9x, produces a price near $900.
That implies roughly $310B market capitalisation on about 335M shares after continued 2% annual repurchases.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-14	565
Observed price	2021-09-22	604
Observed price	2021-10-14	578
Observed price	2021-10-31	638
Observed price	2021-11-09	628
Observed price	2021-11-18	637
Observed price	2021-12-01	634
Observed price	2021-12-18	653
Observed price	2021-12-27	662
Observed price	2022-01-17	591
Observed price	2022-02-04	593
Observed price	2022-02-12	560
Observed price	2022-02-21	532
Observed price	2022-03-02	556
Observed price	2022-03-15	553
Observed price	2022-04-05	591
Observed price	2022-04-10	595
Observed price	2022-04-27	523
Observed price	2022-05-10	529
Observed price	2022-05-23	553
Observed price	2022-06-01	556
Observed price	2022-06-14	507
Observed price	2022-06-27	537
Observed price	2022-07-05	553
Observed price	2022-07-23	556
Observed price	2022-08-13	601
Observed price	2022-08-18	595
Observed price	2022-09-04	545
Observed price	2022-09-13	560
Observed price	2022-09-30	510
Observed price	2022-10-17	524
Observed price	2022-10-22	498
Observed price	2022-11-04	488
Observed price	2022-11-25	553
Observed price	2022-12-13	571
Observed price	2022-12-17	537
Observed price	2022-12-26	545
Observed price	2023-01-16	584
Observed price	2023-02-02	583
Observed price	2023-02-11	570
Observed price	2023-02-15	564
Observed price	2023-02-28	548
Observed price	2023-03-13	547
Observed price	2023-04-04	573
Observed price	2023-04-17	584
Observed price	2023-04-26	551
Observed price	2023-05-04	547
Observed price	2023-05-26	512
Observed price	2023-05-30	516
Observed price	2023-06-17	532
Observed price	2023-06-30	516
Observed price	2023-07-13	527
Observed price	2023-07-26	573
Observed price	2023-08-12	539
Observed price	2023-08-29	556
Observed price	2023-09-07	529
Observed price	2023-09-16	513
Observed price	2023-10-03	499
Observed price	2023-10-07	496
Observed price	2023-10-29	436
Observed price	2023-11-02	446
Observed price	2023-11-24	487
Observed price	2023-11-28	489
Observed price	2023-12-20	529
Observed price	2024-01-02	529
Observed price	2024-01-11	546
Observed price	2024-01-24	543
Observed price	2024-01-28	558
Observed price	2024-02-14	548
Observed price	2024-03-07	595
Observed price	2024-03-11	594
Observed price	2024-03-24	573
Observed price	2024-04-06	581
Observed price	2024-04-19	548
Observed price	2024-05-02	572
Observed price	2024-05-15	597
Observed price	2024-06-06	579
Observed price	2024-06-19	566
Observed price	2024-06-23	561
Observed price	2024-07-11	539
Observed price	2024-07-19	545
Observed price	2024-07-28	610
Observed price	2024-08-14	604
Observed price	2024-09-05	614
Observed price	2024-09-09	619
Observed price	2024-09-22	606
Observed price	2024-10-05	598
Observed price	2024-10-27	551
Observed price	2024-11-04	559
Observed price	2024-11-22	514
Observed price	2024-12-09	533
Observed price	2024-12-18	520
Observed price	2024-12-31	523
Observed price	2025-01-13	556
Observed price	2025-01-17	561
Observed price	2025-01-30	596
Observed price	2025-02-12	535
Observed price	2025-03-01	519
Observed price	2025-03-14	521
Observed price	2025-04-01	491
Observed price	2025-04-05	452
Observed price	2025-04-22	425
Observed price	2025-05-01	424
Observed price	2025-05-23	394
Observed price	2025-06-09	411
Observed price	2025-06-18	401
Observed price	2025-06-22	404
Observed price	2025-07-05	425
Observed price	2025-07-18	426
Observed price	2025-07-27	478
Observed price	2025-08-13	483
Observed price	2025-08-22	493
Observed price	2025-09-08	488
Observed price	2025-09-25	466
Observed price	2025-10-13	527
Observed price	2025-10-26	563
Observed price	2025-10-30	566
Observed price	2025-11-21	588
Observed price	2025-11-25	593
Observed price	2025-12-17	566
Observed price	2025-12-21	574
Observed price	2026-01-07	617
Observed price	2026-01-20	636
Observed price	2026-02-07	539
Observed price	2026-02-11	525
Observed price	2026-02-15	507
Observed price	2026-03-09	502
Observed price	2026-03-13	464
Observed price	2026-04-17	526
Observed price	2026-04-26	477
Observed price	2026-04-30	478
Observed price	2026-05-17	442
Observed price	2026-05-26	455
Observed price	2026-06-08	492
Observed price	2026-06-21	467
Observed price	2026-07-12	529
Observed price	2026-07-21	525
Observed price	2026-08-07	596
Observed price	2026-08-16	586
Observed price	2026-08-25	630
Observed price	2026-09-07	605
Observed price	2026-09-23	665
Observed price	2026-09-24	678
Observed price	2026-09-25	675
Published advisor forecast	2026-09-18	651
Published advisor forecast	2026-12-18	625
Published advisor forecast	2027-03-18	607
Published advisor forecast	2027-06-18	625
Published advisor forecast	2027-09-18	637
Published advisor forecast	2027-12-18	663
Published advisor forecast	2028-03-18	676
Published advisor forecast	2028-06-18	696
Published advisor forecast	2028-09-18	717
Published advisor forecast	2028-12-18	732
Published advisor forecast	2029-03-18	746
Published advisor forecast	2029-06-18	769
Published advisor forecast	2029-09-18	746
Published advisor forecast	2029-12-18	775
Published advisor forecast	2030-03-18	791
Published advisor forecast	2030-06-18	815
Published advisor forecast	2030-09-18	831
Published advisor forecast	2030-12-18	848
Published advisor forecast	2031-03-18	864
Published advisor forecast	2031-06-18	882
Published advisor forecast	2031-09-18	899

2. Scenarios & Signals

Bull case

The bull case activates when the rate regime and the biotech funding cycle turn together. Falling policy rates from 2028 revive small-cap biotech financing, which converts TMO's instrument replacement cycle into a genuine expansion cycle; exceeds the 7% target, PPI leverage pushes adjusted operating margin past 25%, and Clario cross-selling proves the services mix can carry incremental margin. The multiple then holds near 26x instead of compressing, and earnings and valuation advance simultaneously, delivering a return well beyond the base path.

Bear case

The bear case activates when a single soft organic quarter meets a market that has pre-paid for perfection. Growth slips toward 2-3% net of the divestiture drag, sell-side targets that already sit below spot are cut rather than raised, and momentum holders exit into a 5% ten-year yield. A reduced NIH appropriation and Section 232 duties on biomedical inputs then compress both volume and gross margin, while rising leverage limits the buyback's cushion. The multiple reverts toward 19x and the shares surrender most of 2026's gain.

Current crowd narrative

The crowd has decided the life-science-tools winter is over and Thermo Fisher is the safest way to own the thaw. Sell-side capitulated to the tape in September, with UBS lifting its target from $540 to $730 [6], after a 45% advance from May's $449 low. The anchoring bias is stark: 2028's promised 7% is treated as arrival, not aspiration, and the price now sits above the mean analyst target.

Alpha-gap assessment

The crowd modestly overestimates these shares. The operating evidence is genuine, inflected from 1% to 5% and guidance rose, but the market has compressed a three-year normalization into a four-month re-rating and paid 25.9x forward earnings into a 5% ten-year Treasury. The overlooked detail is segmental: the 420 bps margin swing came from cyclical instruments, while the largest segment managed 20 bps. Quality is real; the entry price has borrowed most of the next three years of returns.

Convergence catalyst

The Q3 2026 and Q1 2027 prints are the pressure test. If holds above 4% net of the $200M microbiology drag, the multiple survives; if it slips toward 2-3%, estimate revisions turn and the first sign is the mean target falling back under $600.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: 0.4
Expected volatility regime: moderate
Convergence-cycle position: momentum

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Buyback Engine Shrinks THE Float	Follow the share count, not the revenue line: 371M shares against roughly 394M in 2024, with $3.0B repurchased in Q1 2026 and $1.0B more in Q2 [17][19]. TTM net buyback yield of 2.07% dwarfs the 0.13% dividend, which means roughly a fifth of guided adjusted EPS growth is manufactured below the operating line. With TTM free cash flow of $7.32B, this lever persists through the horizon.	Not available	+13.0%
Instrument Replacement Cycle Wakes UP	Analytical Instruments grew 7% organically with operating margin up 420 bps to 23.0% in Q2 2026 [11]. That is volume leverage off a depressed base after three years of deferred lab capex, and replacement cycles in mass spectrometry and chromatography run six to eight years. Group organic growth inflected from 1% in Q1 to 5% in Q2 [4][8], corroborating that the destocking trough is behind rather than ahead.	Not available	+12.0%
PPI Grinds OUT Margin Quarter BY Quarte	The Practical Process Improvement system is the least glamorous and most reliable part of this story. Management committed to 40-50 bps of annual adjusted operating margin expansion, and Q2 2026 delivered 22.8% versus 21.9% [1][4]. On a ~$48B revenue base, each 50 bps is roughly $240M of incremental operating income with no capital attached, which is why adjusted EPS can grow low-teens on mid-single-digit organic revenue.	Not available	+11.0%
Tariffs Become A Capacity RENT	Onshoring policy taxes importers and pays whoever already owns qualified US GMP lines. Management confirmed a top-ten pharma customer transferring programs into US CDMO capacity for immediate production, and TMO bought a New Jersey sterile fill-finish site to capture it [12][24]. Section 232 pharmaceutical investigations therefore act as a demand recruiter for the bioprocessing and CDMO franchise, an advantage that persists while reshoring mandates remain policy.	Not available	+8.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
THE Recovery IS Already PAID FOR	At 651 the stock trades near 25.9x guided 2026 adjusted EPS of about $25.13 and 34.6x TTM GAAP EPS, above the mean sell-side target [5][9]. The discount rate is moving the wrong way: the US 10Y closed at 4.998% on 18 September 2026 and the Fed's median dot sits at 4.1% for both 2026 and 2027. A long-duration compounder priced for normalization faces mechanical multiple compression.	Not available	-22.0%
NIH Plumbing Throttles NEW Placements	Even if Congress again rejects the headline cut, the mechanics bite. The FY2027 request seeks $41.4B, roughly a 10.5% reduction, and requires multi-year grants to be funded upfront in a single lump sum, which mathematically reduces the number of new awards [20][21][23]. Fewer new awards means fewer first-time instrument placements and consumables pull-through in academic and government, TMO's slowest-recovering end market.	Not available	-9.0%
Growth Bought AT THE LOW Margin END	Look at where the incremental dollar lands. Laboratory Products and Biopharma Services, now the largest segment and the destination of the Clario capital, expanded adjusted operating margin only 20 bps to 14.0% in Q2 2026 [12], while the cyclical instruments segment supplied the headline gain. Group mix is drifting toward services with structurally lower incremental margins, capping the return on invested capital that the 7% organic target implies.	Not available	-8.0%
Leverage Creeps WITH Every DEAL	Debt-to-equity moved from 0.66 at FY2024 to 0.74 at FY2025 to 0.83 cited on the Q2 2026 call [17], with Clario funded by a USD senior-notes offering [16]. Refinancing into a 5% ten-year yield raises the coupon on every maturity rolled, and FY2025 interest coverage of 6.12x, while safe, is half the 2022 level. Deal-plus-buyback appetite competes for the same cash flow.	Not available	-7.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Biotech Funding TAPS Reopen	The trigger would be a credible Fed easing cycle in 2028-2029 once the energy-driven inflation impulse clears, reviving small and mid-cap biotech capital raising. That cohort is the marginal buyer of new instruments and early-stage CDMO slots, so a funding reopening converts TMO's replacement cycle into a genuine expansion cycle, pushing organic growth above the 7% Investor Day target and re-rating the multiple on faster, higher-quality growth. It stays below 50% because the September 2026 dot plot implies rates near 4.1% through 2027, and prior biotech funding recoveries have repeatedly stalled.	33.0%	+27.0%
Portfolio Surgery Unlocks THE Parts	The microbiology sale to Astorg for $1.1B shows management's willingness to prune [12]. A larger move in 2028-2030, separating Specialty Diagnostics or the clinical research services stack, would expose a sum-of-parts gap: a consumables-plus-instruments core deserves a higher multiple than a blended conglomerate of hardware, CRO services and diagnostics. Investors would pay for cleaner organic growth and higher incremental margins. Probability stays low because TMO's operating philosophy favours accumulation over separation, and PPI synergies argue against breaking up the platform.	18.0%	+21.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Multiple Reverts TO ITS Decade MEAN	The decisive trigger is a single quarter where organic growth slips back toward 2-3% net of the $200M microbiology divestiture drag, most plausibly in the Q3 2026 or Q1 2027 print. Because the September 2026 price already exceeds the $590-645 consensus mean target [6][9], estimate revisions cannot cushion the fall; the 25.9x forward multiple would compress toward 20x within two quarters as the momentum cohort exits. It remains below 50% because Q2 evidence and raised guidance genuinely support the inflection.	36.0%	-28.0%
Section 232 Duties LAND ON Inputs	Should the pending Section 232 investigations into biomedical inputs and medical devices produce product-specific tariffs during 2027, TMO's globalised manufacturing and reagent sourcing becomes a cost liability rather than an onshoring advantage [24]. Combined with rare-earth shipment friction affecting instrument components, gross margin compresses just as customers defer capital purchases to absorb their own duties. Probability sits below 50% because life-science research inputs have historically drawn exemptions and TMO's US footprint provides partial mitigation.	28.0%	-19.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_c8599417-4ae6-55a3-a1c3-899ca51e4c74__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	-4.0%	625.39	Momentum cools as the Q3 print absorbs the $200M microbiology divestiture drag and a 5% ten-year yield pressures long-duration multiples. Price sits above mean targets, leaving no revision cushion for an in-line quarter.
2	March 18, 2027	-3.0%	606.63	FY2027 guidance frames mid-single-digit organic growth against fading FX and acquisition tailwinds. The Clario comparison turns organic, exposing underlying demand, while NIH appropriation uncertainty delays academic instrument orders into the second half.
3	June 18, 2027	+3.0%	624.83	Congress again rejects the headline NIH cut, removing a feared overhang. Q1 organic growth near 4% plus continued 40-50 bps margin expansion restores confidence, and buybacks absorb supply at a de-rated entry price.
4	September 18, 2027	+2.0%	637.33	Bioprocessing consumables and CDMO bookings benefit from onshoring transfers into US GMP capacity. Offsetting this, the upfront grant-funding mechanism reduces new academic awards, keeping instrument placements subdued through the summer.
5	December 18, 2027	+4.0%	662.82	Inflation moderates as the energy shock base effect rolls off, easing the discount-rate headwind. Management previews the 2028 step toward 7% organic growth, and the market begins paying for the Investor Day bridge again.
6	March 18, 2028	+2.0%	676.08	FY2028 guidance is the credibility test for the 7% organic target. A cautious initial range near 5-6% keeps enthusiasm contained, while low-teens adjusted EPS growth and continued repurchases support the floor.
7	June 18, 2028	+3.0%	696.36	Clario cross-selling begins showing in LPBS bookings and pharma services backlog. Instrument replacement demand broadens beyond analytical into life sciences solutions, lifting group organic growth toward the upper half of guidance.
8	September 18, 2028	+3.0%	717.25	Easier policy rates start reviving small and mid-cap biotech financing, the marginal buyer of instruments and early-stage CDMO slots. Order intake improves ahead of revenue, and the market pays forward for that leading indicator.
9	December 18, 2028	+2.0%	731.59	Margin expansion continues at the guided 40-50 bps, but mix dilution from services growth caps enthusiasm. Leverage from prior deals limits buyback pace, so per-share accretion slows relative to 2026's aggressive repurchase year.
10	March 18, 2029	+2.0%	746.22	A US election-cycle budget debate revives research-funding uncertainty. Solid FY2029 guidance and pharmaceutical R&D resilience offset the noise, leaving the shares grinding higher in line with earnings rather than re-rating.
11	June 18, 2029	+3.0%	768.61	Bioprocessing capacity utilisation tightens as onshored programs reach commercial scale, lifting consumables pull-through. Adjusted operating margin approaches 24%, validating the PPI compounding mechanism that underwrites low-teens earnings growth.
12	September 18, 2029	-3.0%	745.55	A broad risk-off episode in high-multiple defensives, triggered by renewed inflation or credit stress, compresses valuations across quality compounders. Fundamentals hold, but the multiple absorbs the shock rather than earnings.
13	December 18, 2029	+4.0%	775.38	Recovery follows as the quarter confirms mid-to-high single-digit organic growth and a resumed larger buyback. Investors rotate back into cash-generative healthcare infrastructure after the dislocation, restoring the prior valuation band.
14	March 18, 2030	+2.0%	790.88	FY2030 guidance embeds the mature 7% organic run-rate plus low-teens adjusted EPS growth. With that fully expected, the shares track earnings delivery rather than expanding on narrative, which limits upside per quarter.
15	June 18, 2030	+3.0%	814.61	Portfolio pruning continues as lower-margin units are divested, improving mix and incremental returns on capital. Free cash flow above $9B funds both a mid-sized bolt-on and sustained repurchase of roughly 2% of shares.
16	September 18, 2030	+2.0%	830.90	Precision diagnostics and multiomics platforms add incremental consumables revenue. Competitive pressure from lower-cost Asian instrument makers caps pricing power in mid-tier segments, keeping margin expansion at the guided rate rather than above.
17	December 18, 2030	+2.0%	847.52	Year-end positioning favours cash-generative healthcare infrastructure amid a normalised rate environment near 3.5%. Earnings compound reliably, but the forward multiple settles in the low twenties, capping valuation-driven gains.
18	March 18, 2031	+2.0%	864.47	The company enters a slower reinvestment phase with a larger revenue base, making the 7% organic target arithmetically harder. Buybacks and margin discipline carry per-share growth, sustaining modest appreciation without re-rating.
19	June 18, 2031	+2.0%	881.76	Adjusted EPS approaches the high-thirties, validating the compounding bridge set at the 2026 Investor Day. The market pays a mature-quality multiple near 21-22x, so returns converge on underlying earnings growth.
20	September 18, 2031	+2.0%	899.39	The horizon closes with the shares near $900, reflecting roughly 10% annual EPS compounding offset by multiple compression from 25.9x. Cash generation and float reduction remain the durable per-share value engine.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]What Thermo Fisher CEO Said at Investor Day That the Market Is Still Processing | TIKR.comtikr.com
[2]Thermo Fisher Scientific: TMO Stock Price Quote & News | Robinhoodrobinhood.com
[3]Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Dayir.thermofisher.com
[4]THERMO FISHER SCIENTIFIC INC. - Form 8-K - FY2026sec.gov
[5]Thermo Fisher Scientific Q2 Earnings Call Highlightsfinance.yahoo.com
[6]Thermo Fisher Scientific (TMO) Stock Price & Overviewstockanalysis.com
[7]Thermo Fisher Scientific Inc. (TMO) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
[8]Thermo Fisher (TMO) Sets a Bold 7% Annual Growth Target at Its 2026 Investor Day - Insider Monkeyinsidermonkey.com
[9]Thermo Fisher Scientific (TMO) Stock Forecast & Price Target - Investing.cominvesting.com
[10]TMO Stock Quote Price and Forecast | CNNcnn.com
[11]Thermo Fisher Raised Full-Year Guidance After a Standout Q2 Earnings Call | TIKR.comtikr.com
[12]Thermo Fisher Scientific Inc (TMO) Q2 FY2026 earnings call transcriptfinance.yahoo.com
[13]Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.ir.thermofisher.com
[14]THERMO FISHER SCIENTIFIC INC. - Form 10-Q - FY2026sec.gov
[15]Thermo Fisher Completes $8.875 Billion Acquisition of Clario, Expanding Clinical Trial Data Capabilities | Applied Clinical Trials Onlineappliedclinicaltrialsonline.com
[16]Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notesir.thermofisher.com
[17]Earnings call transcript: Thermo Fisher tops Q2 2026 estimates and lifts outlook By Investing.cominvesting.com
[18]List of 54 Acquisitions by Thermo Fisher Scientific (Aug 2026) - Tracxntracxn.com
[19]Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Reports First Quarter 2026 Resultsir.thermofisher.com
[20]Welcome to the Office of Budget - NIHofficeofbudget.od.nih.gov
[21]Trump’s 2027 budget proposes deep cuts to science programscen.acs.org
[22]Proposed NIH Cuts, Funding Changes Risk Slowing Cancer Research - ASCOasco.org
[23]Pharmaceutical Tariffs Loom, FDA Uses Faulty AI Tool, Research Funding in Jeopardy, and More - Clinical Advisorclinicaladvisor.com
[24]2026 Life Sciences Policy Outlook | ML Strategiesmlstrategies.com
[25]TMO Stock Price Quote - Thermo Fisher Scientific Incmorningstar.com
[26]Free Trialmarketbeat.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Niccolo Machiavelli — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.